Drug intelligence / Profile preview

GH35

Development stage: Phase 1
Modality: Small Molecules
Administration: Oral

Overview

GH35 is an investigational small molecule drug administered in tablet form. It is currently being evaluated in clinical trials for its safety and tolerability in patients with advanced solid tumors that harbor a KRAS G12C mutation. The primary objective of these studies is to determine the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D). The drug is designed to target the specific KRAS G12C mutation, aiming to inhibit its oncogenic activity in cancer cells.

Other names: GH-KRASKRAS G12C inhibitor

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on GH35.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GH35.

Explore the full profile